[18F]-FAPI-04 PET/CT 提高子宫恶性肿瘤根治术后患者转移灶检出:与[18F]-FDG PET/CT 的前瞻性对照研究
前瞻性纳入2022年8月至2024年8月子宫恶性肿瘤根治术后怀疑复发/转移患者36例,同期行[18F]-FDG与[18F]-FAPI-04 PET/CT。局部复发两者诊断效能相当,SUVmax与TBR无显著差异;[18F]-FAPI-04对淋巴结转移检出优于[18F]-FDG(p<0.01),腹部淋巴结最明显;内脏转移摄取参数显著高于[18F]-FDG,以腹膜和脑转移为著。
要点
- [18F]-FAPI-04 PET/CT对子宫恶性肿瘤术后淋巴结转移检出优于[18F]-FDG(p<0.01)。
- 诊断优势在腹部淋巴结、脑及腹膜转移最明显,局部复发两者相当。
- 内脏转移[18F]-FAPI-04的SUVmax与TBR显著高于[18F]-FDG。
核心结论
- [18F]-FAPI-04 PET/CT对子宫恶性肿瘤术后转移灶检出能力优于[18F]-FDG PET/CT,在腹部淋巴结、脑及腹膜转移方面诊断优势尤为明显。
研究设计与样本
- 前瞻性研究,2022年8月至2024年8月纳入根治术后怀疑复发/转移的子宫恶性肿瘤患者36例,同期行[18F]-FDG PET/CT与[18F]-FAPI-04 PET/CT,前瞻性评估影像数据。
关键影像表现/征象
- 局部复发灶两种示踪剂诊断效能相当,SUVmax与TBR无显著差异。
- 淋巴结转移[18F]-FAPI-04检出优于[18F]-FDG(p<0.01),腹部淋巴结转移诊断优势最明显。
- 内脏转移灶[18F]-FAPI-04的SUVmax与TBR显著高于[18F]-FDG,腹膜和脑转移尤为突出。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This prospective study aimed to investigate the potential of [18F]-fibroblast activation protein inhibitor ([18F]-FAPI)-04 PET/CT for evaluating suspected recurrent uterine malignancy after radical surgery, and prospectively compared it with [18F]-Fluorodeoxyglucose ([18F]-FDG) PET/CT.
METHODS: From August 2022 to August 2024, patients with suspected recurrent/metastatic uterine malignancy following radical surgery received both [18F]-FDG PET/CT and [18F]-FAPI-04 PET/CT examinations, with imaging data prospectively evaluated. The comparative diagnostic efficacy of two PET/CT modalities for recurrence detection was statistically assessed using McNemar's test and the difference of lesion tracer uptake parameters [Maximum standardized uptake value (SUVmax) and Tumor-to-Background Ratio (TBR)] were analyzed by Wilcoxon signed-rank tests.
RESULTS: 36 patients with 482 local relapses and distant metastases were included. Local relapses demonstrated comparable diagnostic performance between [18F]-FAPI-04 and [18F]-FDG PET/CT, with no significant differences in SUVmax and TBR. In nodal metastases assessment, [18F]-FAPI-04 PET/CT exhibited superior detection capability over [18F]-FDG PET/CT (p < 0.01), with the diagnostic advantage most evident in abdominal lymph node metastases. Visceral metastatic lesions demonstrated significantly elevated [18F]-FAPI-04 PET/CT uptake parameters (SUVmax and TBR) compared to [18F]-FDG PET/CT imaging, especially in peritoneal and brain metastases.
CONCLUSIONS: [18F]-FAPI-04 PET/CT demonstrated superior detection capability for postoperative metastatic lesions in uterine cancer patients compared to [18F]-FDG PET/CT, with particularly diagnostic advantage in abdominal lymph node, brain, and peritoneal metastases.
引用
- Chen H, Peng H, Liang J, et al. [18F]-FAPI-04 PET/CT improves metastatic lesions detection for patients with uterine malignancy after radical surgery: prospectively compared with [18F]-FDG PET/CT. Eur J Radiol. 2025. PMID: 40609258. doi:10.1016/j.ejrad.2025.112270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。